Investor Lawsuits Mount Against Semler Scientific Over Undisclosed DOJ Probe

Medical technology firm Semler Scientific faces a growing wave of investor litigation following revelations about a long-concealed Department of Justice investigation. The company stands accused of deliberately misleading shareholders about significant regulatory risks, triggering substantial stock declines when the information finally became public.

Undisclosed Investigation and Multi-Million Dollar Settlement

Central to the controversy is the marketing of Semler’s QuantaFlo technology to Medicare. Federal authorities have been examining potential violations of the False Claims Act since July 2017—a material fact allegedly concealed from investors for years. The company’s annual report, published in late February 2025, contained the first vague reference to these regulatory challenges, immediately sending shares tumbling by 9.4%.

The situation escalated dramatically in April 2025 when Semler reached a settlement agreement with regulators, agreeing to pay $29.75 million. This announcement prompted another wave of selling that drove the stock down nearly 10% further.

Should investors sell immediately? Or is it worth buying Semler Scientific?

Class Action Deadline Approaches

Multiple law firms have now filed securities class actions alleging fraud and intentional deception through omission of material information. Investors who purchased Semler shares between March 2021 and April 2025 and suffered losses have until October 28, 2025 to seek lead plaintiff status in these proceedings.

Unconventional Financial Strategy Adds Complexity

Adding another layer of uncertainty to the investment thesis, Semler reportedly considered leveraging its Bitcoin reserves to fund the multimillion-dollar settlement payment. This unconventional approach to corporate finance is particularly unusual for a medical technology company and introduces additional considerations for stakeholders evaluating the company’s risk profile.

The convergence of regulatory challenges, mounting legal actions, and unconventional financial management presents investors with complex valuation questions. Market participants must determine whether recent price movements represent an overreaction or reflect fundamental challenges facing the business.